论文部分内容阅读
目的观察泰索帝联合顺铂方案治疗蒽环类耐药性晚期乳腺癌的疗效与安全性。方法2000年4月至2005年3月,以泰索帝联合顺铂方案治疗蒽环类耐药性晚期乳腺癌31例。泰索帝75 mg/m~2,静滴,第1天；顺铂75 mg/m~2,静滴,第1天加水化、利尿、止吐等治疗；21 d为1周期。本组中位化疗周期数为4(2～8)周期。结果31例均可评价疗效。完全缓解(CR)2例(6．5%),部分缓解(PR)15例(48．4%),稳定(SD)7例(22．6%),进展(PD)7例(22．6%),总有效率(CR+PR) 54．9%,中位肿瘤进展时间(TTP)5个月。1年生存率66．7%。主要毒性为恶心、呕吐和骨髓抑制。结论泰索帝和顺铂联合方案治疗蒽环类耐药性晚期乳腺癌疗效较好,使用方便,毒性反应较轻,是蒽环类耐药性乳腺癌的有效解救治疗方案。
Objective To observe the efficacy and safety of taxotere combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer. Methods From April 2000 to March 2005, 31 patients with anthracycline-resistant advanced breast cancer were treated with taxotere combined with cisplatin. Taxotere 75 mg / m ~ 2, intravenous infusion, on the first day; cisplatin 75 mg / m ~ 2, intravenous infusion, the first day of hydration, diuretic, antiemetic and other treatment; The median number of cycles of chemotherapy in this group is 4 (2 ~ 8) cycles. Results 31 cases can evaluate the curative effect. There were 2 cases (6.5%) of complete remission (CR), 15 cases (48.4%) of partial remission (PR), 7 cases of stable (SD) and 22.6 cases of progression (PD) 6%), total effective rate (CR + PR) 54.9%, median tumor progression time (TTP) 5 months. 1-year survival rate of 66.7%. The main toxicity is nausea, vomiting and myelosuppression. Conclusion Combination of taxotere and cisplatin in the treatment of advanced anthracycline-resistant breast cancer has better curative effect, convenient use and less toxic reaction, which is an effective rescue treatment for anthracycline-resistant breast cancer.